Merck Serono has published results from the Phase III trial of its investigational MUC1 antigen specific cancer immunotherapy tecemotide (also known as L-BLP25) in patients with unresectable, locally advanced Stage III non-small cell lung cancer (NSCLC), known as the START* trial, in The Lancet Oncology.   Data included in the publication, and first presented at the American Society of Clinical Oncology (ASCO) 2013, showed that the primary endpoint of overall survival (OS) was not met. Media...